º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Stay of execution for huge Novartis pharmaceutical plant

Grimsby site to be retained for a further year after initial 2020 closure pushed back

Building 150 at Novartis Grimsby.(Image: Novartis)

Grimsby’s Novartis plant has been granted a 12-month stay of execution.

Production of two of the key drugs the global pharmaceutical giant manufactures on the South Humber Bank is required for a further year.

The company said demand has increased as health authority approvals on manufacturing are awaited elsewhere.

It means two of the three buildings - and a large proportion of the staff - will now be retained throughout 2021, having been scheduled to close at the end of this year.

It will be seen as a huge short-term boost to the local economy, retaining a high-skilled site, as  the wake left by the coronavirus pandemic is expected to lead to immediate recession. 

The huge plant employed 400 people when the axe fell back in September 2018, with salaries alone pumping £23 million into the area.

Ian Johnson, managing director of Novartis Grimsby Ltd.(Image: Novartis)

The first phase of redundancies has been between January and June, with numbers described as in their dozens.

A first production run ended on Monday, with the last batch from Building 110. Buildings 120 and 150 will now continue for a further 18 months, with site power, warehousing and maintenance staff also retained to a level now being determined.